+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying the effectiveness and safety of combining inavolisib with a cyclin-dependent kinase 4 and 6 inhibitor CDK46i and letrozole compared to placebo with CDK46i and letrozole. This study focuses on adults with endocrine-sensitive PIK3CA-mutated hormone receptor-positive, HER2-negative advanced breast cancer. The trial is a phase III, randomized, double-blind, placebo-controlled study aiming to improve first-line treatment options for this condition. Participants will be randomly assigned to receive either oral inavolisib once daily alongside letrozole and a CDK46 inhibitor or a matching placebo with letrozole and CDK46 inhibitor. The CDK46 inhibitor is given on either days 1-21 or days 1-28 of each 28-day treatment cycle. Both groups will follow this treatment regimen throughout the study period. During the trial, participants will be monitored regularly to assess progression-free survival, overall survival, and various measures of treatment response and quality of life, including pain and physical function. Safety will be closely tracked by recording adverse events and treatment-related symptoms using patient-reported outcomes. The study may last up to seven years, including long-term follow-up to evaluate the effects of the treatments over time.

Age: 18Years +All GendersPhase 3
242 locations
P

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and how the body processes pharmacokinetics several treatment combinations for participants with multiple myeloma, a type of blood cancer. This platform study allows new treatment substudies to be added as new options become available. Two specific substudies focus on different treatment combinations and participant groups based on their disease status and prior therapies. One substudy explores the combination of cevostamab and lenalidomide as maintenance therapy after stem cell transplant in patients with high-risk features who have responded to initial treatment. Cevostamab is given intravenously in a cycle of 28 days with an initial dose escalation phase, while lenalidomide is taken orally in 28-day cycles. Another substudy assesses the combination of cevostamab with iberdomide for participants with relapsed or refractory multiple myeloma who have undergone multiple prior treatments. Cevostamab is administered intravenously every 21 days, and iberdomide is taken orally on a 21-day cycle. Participants will be involved in scheduled dosing cycles with regular assessments and procedures. Researchers will monitor adverse events, response rates, progression-free survival, overall survival, and pharmacokinetic parameters up to approximately five years. Safety is closely observed, including management of potential side effects like cytokine release syndrome treated with tocilizumab if needed. The study includes multiple visits for dosing and evaluation, with long-term follow-up to assess outcomes and treatment effects.

Age: 18Years +All GendersPhase 1Phase 2
16 locations
E

Actively Recruiting

Researchers are evaluating the safety, tolerability, how the body processes pharmacokinetics, and effects pharmacodynamics of the drug cevostamab alone and in combination with other medications in participants with relapsed or refractory multiple myeloma. This is an open-label Phase Ib trial that aims to understand how cevostamab works and its safety when given with pomalidomide and dexamethasone or daratumumab and dexamethasone. The study enrolls adults with this form of multiple myeloma who have had prior treatments. Participants receive cevostamab intravenously on different schedules depending on their assigned group. One group receives cevostamab alone in 28-day cycles with a modified weekly schedule. Another group receives cevostamab plus pomalidomide taken orally and dexamethasone on a two-week then four-week cycle schedule. A third group receives cevostamab with daratumumab administered subcutaneously and dexamethasone on 21-day cycles initially, then 28-day cycles later. Tocilizumab may be given if needed to treat certain side effects. Treatment duration varies by group, with some participants having options to continue or re-treat under specified conditions. Throughout the study, participants undergo various assessments including bone marrow biopsies and blood tests to monitor safety, treatment response, and drug levels. Researchers track dose adjustments, side effects, and response rates up to approximately four years. The study also monitors survival outcomes and immune responses. Participants health and disease status are regularly evaluated during and after treatment to gather comprehensive data about the investigational therapies.

Age: 18Years +All GendersPhase 1
34 locations
P

Actively Recruiting

Researchers are studying the effectiveness and safety of Afimkibart as an induction and maintenance treatment for people with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to evaluate how well Afimkibart works compared to a placebo in managing this condition. Participants will be randomly assigned to receive either Afimkibart or a placebo. Those receiving Afimkibart will get an intravenous IV infusion followed by subcutaneous SC injections. The study includes two experimental groups receiving Afimkibart and one group receiving placebo, both administered by IV and SC methods. The treatment and follow-up period extends through 52 weeks to assess both induction and maintenance therapy effects. During the study, participants will undergo evaluations including the Crohns Disease Activity Index CDAI for clinical remission and endoscopic assessments at week 52. Additional measurements at week 12 and throughout the study include symptom tracking, stool frequency, abdominal pain, quality of life questionnaires, and monitoring of adverse events. The total study duration may extend up to 70 weeks for safety follow-up and outcome assessments.

Age: 16Years - 80YearsAll GendersPhase 3
375 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of induction therapy using Afimkibart also called RO7790121 in adults with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to determine whether this treatment can induce clinical remission and improve endoscopic response compared to placebo. The trial is led by Hoffmann-La Roche and focuses on participants aged 16 to 80 years who have an inadequate response or intolerance to other Crohns disease treatments. Participants are randomly assigned to one of two groups one group receives Afimkibart initially through intravenous infusion followed by subcutaneous injections, while the other group receives a placebo intravenous infusion followed by Afimkibart subcutaneous injections. The study follows a parallel design with double-blinding to compare the effects of these treatment approaches over a 12-week induction period. During the trial, participants will undergo assessments including Crohns Disease Activity Index scoring, endoscopic evaluations, and symptom tracking such as stool consistency, abdominal pain, and fatigue. Researchers will monitor clinical remission, symptomatic relief, and adverse events up to 30 weeks after baseline. Quality of life will be measured with questionnaires, and biomarker subgroups will be analyzed. The studys total duration extends through 2033, with key measurements taken at week 12.

Age: 16Years - 80YearsAll GendersPhase 3
208 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of inavolisib combined with Phesgo compared to placebo with Phesgo as maintenance treatment after initial therapy in people with untreated HER2-positive advanced breast cancer that has a PIK3CA mutation. This phase III trial focuses on how well the treatments control the disease and their side effects. Participants first receive induction therapy with Phesgo plus taxane-based chemotherapy. Afterward, they receive maintenance therapy with either inavolisib plus Phesgo or placebo plus Phesgo in 21-day cycles. Phesgo is given by subcutaneous injection every 3 weeks, while inavolisib or placebo tablets are taken daily on days 1 to 21 of each cycle. Optional endocrine therapy may also be provided according to standard care. During the study, participants undergo regular assessments including tumor evaluations, heart function tests, laboratory tests, and quality of life questionnaires. Researchers monitor progression-free survival up to about 40 months and overall survival and other outcomes up to approximately 111 months. Participants are followed closely for adverse events and drug levels. The total study duration may extend up to nearly 10 years, with visits scheduled throughout treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
192 locations
S

Actively Recruiting

Researchers are studying afimkibart also known as RO7790121 to understand how it may affect the bodys processing of certain medicines that rely on cytochrome P450 enzymes in people with moderately to severely active ulcerative colitis UC. This Phase 1, open-label study focuses on the drug-drug interaction potential by observing changes in the pharmacokinetics of enzyme substrates used in medication metabolism. Participants will receive doses of afimkibart along with a cocktail of cytochrome P450 enzyme substrates, including drugs like midazolam, omeprazole, dextromethorphan, warfarin, and caffeine. The study includes a disease-drug-drug interaction phase followed by an optional long-term extension phase where participants may continue treatment and monitoring. During the study, participants will be monitored through blood tests measuring drug levels and enzyme activity up to approximately 13 weeks. Researchers will evaluate various pharmacokinetic outcomes such as drug concentration over time and metabolite ratios. Safety assessments, including adverse event tracking and serum concentration of afimkibart, will continue for up to 5 years, with the total study participation lasting several years depending on extension enrollment.

Age: 18Years - 60YearsAll GendersPhase 1
18 locations
E

Actively Recruiting

This research aims to evaluate the safety and effectiveness of a combination treatment including cevostamab, pomalidomide, and dexamethasone compared to the current standard of care in adults with multiple myeloma. Participants have previously received one to three treatments and were exposed to anti-CD38 monoclonal antibodies and lenalidomide, addressing the need for new options after prior therapies. Participants in one group will receive cevostamab intravenously on a 21-day cycle for the first cycle and then every 28 days thereafter, along with oral pomalidomide starting from the second cycle every 28 days. Dexamethasone is given as a premedication before cevostamab. The other group will receive the investigators choice of standard treatment regimens. Both treatments are monitored over an extended period to assess outcomes. Throughout the study, participants will undergo regular evaluations including disease measurements and quality of life assessments using validated questionnaires. Researchers will track responses such as complete remission and progression-free survival for up to five years after enrollment. Safety will be monitored by recording adverse events and treatment tolerability. This long-term follow-up allows comprehensive assessment of treatment impact and participant well-being.

Age: 18Years +All GendersPhase 3
93 locations
P

Actively Recruiting

Researchers are studying obefazimod to evaluate its effectiveness and safety as a treatment for adults with moderately to severely active Crohns disease who have not responded well or cannot tolerate conventional or advanced therapies. This Phase 2b trial compares obefazimod with a placebo to see if it can help control symptoms and improve disease activity. The study also aims to assess the long-term safety and tolerability of obefazimod during an extension period. The study includes three treatment phases a 12-week induction phase, a 40-week maintenance phase, and a 48-week extension phase. Participants receive one of four daily treatments obefazimod at doses of 50mg, 25mg, or 12.5mg, or a placebo. All treatments are taken once daily, ideally in the morning with food. The extension phase focuses on monitoring safety and tolerability compared to placebo. Participants will attend regular study visits for assessments including the Crohns Disease Activity Index and endoscopic scores to measure disease activity and response. Safety is monitored through adverse event reports and laboratory tests, including blood work for hematology, coagulation, and biochemistry at various weeks up to the end of the study. The total study duration spans several phases, allowing close observation of treatment effects and safety over time.

Age: 18Years - 75YearsAll GendersPhase 2
149 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness and safety of RO7771950 combined with trastuzumab and capecitabine compared to tucatinib with trastuzumab and capecitabine in people with locally advanced or metastatic HER2-positive breast cancer. This study includes patients with or without brain metastases and aims to provide new insights into treatments for this serious condition. The trial is a randomized, open-label study sponsored by Hoffmann-La Roche and involves multiple centers. Participants will be assigned to one of three groups two groups receive different doses of RO7771950 orally twice a day along with trastuzumab and capecitabine, while the third group receives tucatinib orally twice a day with the same combination of trastuzumab and capecitabine. Trastuzumab is given either intravenously or subcutaneously according to local guidelines, and capecitabine is taken orally twice daily. The study includes two parts and is designed to adapt as it progresses to ensure the best evaluation of treatments. During the trial, participants will be closely monitored through various assessments including imaging to measure tumor progression, quality of life evaluations, and safety checks such as heart function tests and monitoring of side effects. The main measure of success is progression-free survival over about 35 months. Other outcomes include overall survival, response rates, and symptom changes, with follow-ups continuing up to about 53 months. Participants will have regular visits for treatment and evaluations throughout the study period.

Age: 18Years +All GendersPhase 2Phase 3
206 locations

1-10 of 11

1